These data are contradictory to that observed by Azambuja et al. [27], who found that there was no significant association between CD86+ /or CD163+ TAM (by IHC) and the relevant clinico-pathological features of the patients, OS and DFS rates in 265 well characterized cHL patients from USA. Here, CD86 is linked to classic Hodgkin lymphoma.